Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
In the 40 years since the HIV epidemic first came to light, treatment options for those infected have come a long way. During January 2021, the FDA approved ViiV Healthcare’s Cabenuva as the very first once-a-month injection for HIV patients. But the Research Triangle pharma is not satisfied yet.
Alloy Therapeutics and Pyxis Oncology announced the formation of their joint venture, Kyma Therapeutics, which will develop immune-modulating antibodies in an attempt to tackle cancer and autoimmune diseases.
Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.
Blackstone Group Inc. is investing $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant’s largest-ever bet on drug development.
Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.
GlaxoSmithKline offered concessions to address EU antitrust concerns over the planned joint venture with Pfizer’s consumer health business, the European Commission said.
Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.
UnitedHealth Group’s Optum unit is suing David Smith, a former information technology executive, for breach of contract.
GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.